News & Insights
February 3, 2026 Heather Bañuelos discusses the FDA increasingly citing promotional claims based on time-to-event endpoint data from single-arm trials
September 10, 2025 Heather Banuelos comments on the FDA issuing about 100 letters directing sponsors to cease violative promotions under a new “crackdown” on deceptive drug advertising that targeted DTC risk-benefit balance problems
June 17, 2025 Heather Bañuelos discusses the U.S. Food and Drug Administration’s launching a burst of enforcement activity targeting prescription drug promotion
November 20, 2023 Heather Banuelos discusses the FDA’s final rule on the presentation of the "major statement" about a prescription drug's side effects and contraindications in direct-to-consumer television and radio ads